Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1915P - The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial


17 Sep 2020


E-Poster Display


Christine Dierks


Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293


C. Dierks1, J. Seufert2, J. Ruf3, J. Duyster1, O. Thomusch1, C. Miething1, A. Zielke4

Author affiliations

  • 1 Hematology/oncology Department, Universitätsklinik - Klinik für Innere Medizin I, 79106 - Freiburg im Breisgau/DE
  • 2 Endocrinology, Universitätsklinik - Klinik für Innere Medizin I, 79106 - Freiburg im Breisgau/DE
  • 3 Nuclear Medicine, Universitätsklinik - Klinik für Innere Medizin I, 79106 - Freiburg im Breisgau/DE
  • 4 Endocrine Surgery, Diakonie Klinikum Stuttgart, 70176 - Stuttgart/DE


Abstract 1915P


Anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) have a dismal prognosis despite multimodal therapy. Tumors are high proliferative, with increased mutational burden (TMB) and enhanced PD-L1 levels, implicating effectiveness of antiproliferative agents (lenvatinib) and immune checkpoint inhibitors (pembrolizumab).


The lenvatinib/pembrolizumab combination was examined within a prospective phase II trial (ATLEP, Anaplastic Thyroid Carcinoma Lenvatinib Pembrolizumab, EudraCT No. 2017-004570-3) in 20 ATC/PDTC pts (16 ATC/4 PDTC), and in a retrospective study including 8 pts (6 ATC/2 PDTC) and follow up over 3 years. Lenvatinib was started with 20/24 mg daily; pembrolizumab (200 mg) was given i.v. every 3 weeks for up to 36 months. Patient tumors were characterized by WES and PD-L1 expression (TPS 1-90%).


a) Retrospective analysis: BOR in ATCs was 66% CR (4/6), 16% SD and 16% PD. BOR in PDTCs was PR (2/2). Median PFS was 17.75 mo for all pts, and 16.5 mo for ATCs, with treatment durations ranging from 1 to 40 mo. Grade III/IV toxicities evolved in 4/8 pts, requiring dose reduction/discontinuation of lenvatinib. Median OS was 18.5 mo for all pts, and 17.5 mo for ATCs, with 3 ATC being alive without relapse (40, 27 and 19 mo) despite metastasized disease at treatment start. All pts with long-term (> 2 years) or CR had either increased TMB or PD-L1 TPS > 50%. b) ATLEP trial: The primary endpoint ORR at 3 months was reached for all 20 pts and is 30% (6/20 PR). Current BOR is 40% PR for all pts (8/20) and 37.5% PR for ATCs only (6/16). All other pts have reached a SD: 60% SD (12/20) for all, 62.5% SD for ATCs only (10/16). PFS and OS are not reached. CTCAE grade III/IV toxicities included aspergillus pneumonia (3/20 pts), hemorrhage (2/20) and fistulas (3/20).


Our results implicate that a combination of lenvatinib and pembrolizumab is safe and effective in patients with ATC or PDTC, including complete and long-term remissions. As the primary endpoint was reached, the phase II ATLEP trial will be extended to 20 more patients (20 ATCs/20 PDTCs total).

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

University of Freiburg.


University of Freiburg.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings